- Trials with a EudraCT protocol (65)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
65 result(s) found for: Triple X syndrome.
Displaying page 1 of 4.
EudraCT Number: 2020-005200-19 | Sponsor Protocol Number: I-CONIC | Start Date*: 2022-05-09 |
Sponsor Name:Västra Götalandsregionen/Onkologiska kliniken | ||
Full Title: Use of Imatinib to convert triple negative breast cancer into ER-positive breast cancer - "I-CONIC" | ||
Medical condition: Early Triple Negative Breast Cancer planned for surgery. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004384-39 | Sponsor Protocol Number: ABCSG-45 | Start Date*: 2018-12-18 | |||||||||||
Sponsor Name:Austrian Breast & Colorectal Cancer Study Group (ABCSG) | |||||||||||||
Full Title: A prospective, open, randomized, phase II study of carboplatin/olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive ... | |||||||||||||
Medical condition: Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003998-17 | Sponsor Protocol Number: ONCOGHdC2015-01 | Start Date*: 2017-02-16 |
Sponsor Name:Grand Hôpital de Charleroi | ||
Full Title: A phase Ib/II study of Durvalumab (MEDI4736) combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE) | ||
Medical condition: patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003693-33 | Sponsor Protocol Number: CDX011-04 | Start Date*: 2016-01-18 | |||||||||||
Sponsor Name:Celldex Therapeutics, Inc. | |||||||||||||
Full Title: A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer | |||||||||||||
Medical condition: Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) DE (Completed) AT (Prematurely Ended) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002264-41 | Sponsor Protocol Number: P160932J | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Etude randomisée multicentrique évaluant l’efficacité et la tolérance de l’infliximab comparativement au Cyclophosphamide dans les formes sévères de maladie de Behçet " Multicenter, randomized, pro... | |||||||||||||
Medical condition: Induction Therapy with Anti-TNF vs Cyclophosphamide in severe Behçet disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024152-29 | Sponsor Protocol Number: | Start Date*: 2011-09-02 | |||||||||||
Sponsor Name:University Hospital of Tübingen | |||||||||||||
Full Title: Canakinumab for Behçet`s Disease Resistant to Standard Treatment (CanBeDisT) | |||||||||||||
Medical condition: Behçet`s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006083-45 | Sponsor Protocol Number: CBKM120ZES02T/SOLTI-1103 | Start Date*: 2012-03-20 | |||||||||||
Sponsor Name:SOLTI (Grupo Español de Estudio, Tratamiento y Otras Estrategias Experimentales en Tumores Sólidos) | |||||||||||||
Full Title: A phase II trial of BKM120 (a PI3K inhibitor) in patients with triple negative metastatic breast cancer | |||||||||||||
Medical condition: triple negative metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000189-45 | Sponsor Protocol Number: | Start Date*: 2018-03-26 |
Sponsor Name:University of Padova | ||
Full Title: Adjuvant treatment for high-risk triple negative breast cancer patients with the anti-pd-l1 antibody Avelumab: A phase III randomized trial | ||
Medical condition: High risk triple negative (ER negative, PR negative, HER2 negative) breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004796-23 | Sponsor Protocol Number: REP0114 | Start Date*: 2015-07-06 | |||||||||||
Sponsor Name:Dompé Farmaceutici s.p.a. | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Can... | |||||||||||||
Medical condition: Metastatic triple negative Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Completed) IT (Completed) ES (Completed) PL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000113-20 | Sponsor Protocol Number: ABI-007-MBC-001 | Start Date*: 2013-07-23 | ||||||||||||||||
Sponsor Name:Abraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation | ||||||||||||||||||
Full Title: A PHASE 2/3, MULTI-CENTER, OPEN-LABEL, RANDOMIZED STUDY OF WEEKLY nab®-PACLITAXEL IN COMBINATION WITH GEMCITABINE OR CARBOPLATIN, COMPARED TO GEMCITABINE/CARBOPLATIN, AS FIRST LINE TREATMENT IN SUB... | ||||||||||||||||||
Medical condition: ER, PgR, and HER2 negative (triple negative) metastatic breast cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: AT (Prematurely Ended) ES (Completed) DE (Prematurely Ended) GB (Prematurely Ended) IT (Completed) PT (Prematurely Ended) GR (Prematurely Ended) FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-003906-26 | Sponsor Protocol Number: ZEN003694-004 | Start Date*: 2019-08-22 | |||||||||||
Sponsor Name:Zenith Epigenetics Ltd. | |||||||||||||
Full Title: A Phase 2 Study of ZEN003694 in Combination with Talazoparib in Patients with Triple-Negative Breast Cancer | |||||||||||||
Medical condition: Triple Negative Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002361-22 | Sponsor Protocol Number: D5336C00001 | Start Date*: 2017-12-05 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatm... | |||||||||||||
Medical condition: Triple negative Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) ES (Ongoing) PL (Trial now transitioned) BE (Completed) FR (Completed) IE (Completed) NL (Completed) PT (Trial now transitioned) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001128-11 | Sponsor Protocol Number: BO20289 | Start Date*: 2007-12-14 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd, Pharmaceuticals Divison, PDR | |||||||||||||
Full Title: An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer. | |||||||||||||
Medical condition: Early primary invasive adenocarcinoma of the breast (triple negative and/or basel-like phenotype) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) AT (Completed) NL (Completed) BE (Completed) CZ (Completed) GR (Completed) FI (Completed) DE (Completed) IT (Completed) ES (Completed) PT (Completed) SE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004358-32 | Sponsor Protocol Number: IJB–TNBC–1–RHEA | Start Date*: 2015-05-07 | |||||||||||
Sponsor Name:Institut Jules Bordet | |||||||||||||
Full Title: Biomarker Research Study for PF-03084014 in cHEmoresistant triple negative breast cAncer - “RHEA” study | |||||||||||||
Medical condition: patients with chemoresistant, triple-negative breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001484-23 | Sponsor Protocol Number: Triple-B | Start Date*: 2013-05-24 | |||||||||||
Sponsor Name:BOOG Study Center | |||||||||||||
Full Title: Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumaB as first-line treatment in advanced triple negative Breast cancer | |||||||||||||
Medical condition: Metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002286-30 | Sponsor Protocol Number: A8641020 | Start Date*: 2014-12-12 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: PHASE 2 STUDY OF SINGLE-AGENT PF 03084014 IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORS | |||||||||||||
Medical condition: ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) IT (Completed) BE (Prematurely Ended) ES (Completed) DE (Completed) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003093-13 | Sponsor Protocol Number: BREAKFAST | Start Date*: 2020-01-14 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
Full Title: Targeting triple negative BREAst cancer metabolism with a combination of chemotherapy and a diet mimicking FASTing plus/minus metformin in the preoperative setting: the BREAKFAST trial | |||||||||||||
Medical condition: Targeting triple negative BREAst cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002108-25 | Sponsor Protocol Number: CC-10004-BCT-002 | Start Date*: 2015-06-17 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY, FOLLOWED BY AN ACTIVE-TREATMENT PHASE TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE... | |||||||||||||
Medical condition: SUBJECTS WITH ACTIVE BEHÇET’S DISEASE | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001651-40 | Sponsor Protocol Number: Phaon1 | Start Date*: 2020-11-13 | |||||||||||
Sponsor Name:palleos healthcare GmbH | |||||||||||||
Full Title: An adaptive randomized neoadjuvant two arm trial in triple-negative breast cancer comparing a mono Atezolizumab window followed by a Atezolizumab - CTX therapy with Atezolizumab – CTX therapy (neoM... | |||||||||||||
Medical condition: ER negative, PR negative and HER2 negative (triple negative) breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006437-40 | Sponsor Protocol Number: TMC114HIV3006 | Start Date*: 2007-02-05 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A randomised, controlled, opel-label trial to compare the efficacy, safety and tolerability of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination ... | |||||||||||||
Medical condition: HIV-1 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) HU (Completed) DK (Completed) DE (Completed) PT (Completed) ES (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
